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To the editor, 
A vast array of in vivo experimental models are utilised within the wound healing field. There 
remains little agreement as to the optimal in vivo experimental approach to mimic human 
chronic wounds (Wilhelm et al., 2017). Moreover, animal models of impaired healing have 
performed particularly poorly at translating drug based therapies to the clinic over many 
years, leading many to question their effectiveness (Gordillo et al., 2013). We have 
previously shown that the wound type (i.e. incision or excision) and subsequent analysis 
method will determine the sensitivity, and hence the likelihood of a statistically significant 
difference being correctly identified using a specific healing model (Ansell et al., 2014). 
When considered alongside our demonstration that rodent hair cycle can significantly alter 
the speed of repair (Ansell et al., 2011), careful experimental design of in vivo wound models 
becomes critical for maximising the probability of achieving statistical significance. Indeed 
the paucity of new drug based therapies emerging for the treatment of chronic wounds may 
be, at least in part, due to sub-optimal preclinical models.  
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Diabetes mellitus (DM) is a major cause of human chronic wounds (Eming et al., 2014). 
Several rodent models of DM are available (Ansell et al., 2012, Boyko et al., 2017, Davidson, 
1998) however, the Streptozotocin (STZ)-induced DM model is almost exclusively used to 
model type 1 DM (Goodson and Hung, 1977). Like other wound models there is an inherent 
lack of consistency between published STZ-DM studies with variation in animal gender, 
wound size and wound type, but also in the length of time between DM-induction and 
subsequent injury (Table 1). We predict this latter variable to be crucial given that numerous 
effects of hyperglycaemia can take many weeks to manifest, such as advanced glycation end-
product accumulation (Chen et al., 2009), or structural features of neuropathy  (Biessels et al., 
2014). To our knowledge, a rigorous assessment of the degree of healing impairment in the 
STZ model linked to time post induction has not been published.  
To begin to fill this knowledge gap, we first examined wound healing following STZ-induced 
DM in male Wistar rats as this gender and strain combination is frequently used (Table 1). 
We compared healing in rats at 3- (n=6 rats) or 6-weeks (n=4 rats) post-DM induction to non-
diabetic (n=6 rats) sham control rats (6mm punch biopsy wound harvested at 5 days post-
wounding; see supplemental methods for full details), to assess the influence of time post-
induction on healing outcome.   
We collected wound photographs at day 5 (Figure 1a), which when assessed revealed a 
significant delay in healing (larger wound surface area) versus control only in 6-week post-
DM induction animals (Figure 1b). To confirm this observation we profiled standardised 
histological wound parameters from tissue sections from the centre of each wound (Figure 
1c). We found no statistically significant difference in histological wound width (Figure 1d) 
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or the area of wound granulation tissue (Figure 1e). Taken together, these data suggest that 
planimetry is a more reliable measure of overall healing delay in the STZ-DM model. 
Histological analysis, however, has merits with the parameter of re-epithelialisation 
demonstrating a statistically significant delay reduction (i.e. delayed wound closure) 
following 6 weeks of DM (Figure 1f). Again, there was only a trend towards delayed re-
epithelialisation in rats 3 weeks post-DM induction. Thus, re-epithelialisation appears to 
provide a sensitive histological readout for the onset of impaired healing with DM.  
The inability to statistically demonstrate any aspect of delayed healing at 3 weeks post-STZ-
DM induction suggests that this (or any earlier) time point is insufficient, despite being used 
frequently in the literature (Table 1). We do however note a trend towards reduced re-
epithelialisation at 3 weeks, which might become statistically detectable with increased 
sample sizes (Table S1). Many studies do not confirm whether significantly delayed repair 
exists with their chosen impaired healing model and sample size (Table 1). Furthermore, 
almost one third of studies do not indicate the DM induction timeframe used. 
That only some wound parameters are demonstrably altered at 6 weeks post-STZ-DM 
induction suggests that the rate at which individual repair processes become impaired 
following loss of blood glucose control differs. To further explore this point we assessed 
changes in inflammation, collagen deposition and angiogenesis, with time-post STZ-DM 
induction. We find a strong increase in the number of wound macrophages in the 6 week 
STZ-DM group (Figure 1g), with no detectable difference in collagen deposition or 
angiogenesis (Figure 1h, 1i). While these data suggest that impairment of angiogenesis and 
collagen deposition take longer than 6 weeks post-STZ-DM, we cannot exclude our single 
analysis timepoint (day 5) providing a poor readout for these later phases of repair.  
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Pain withdrawal time in DM rats only declines 4-6 weeks post STZ administration (Kambiz 
et al., 2015), so few wounding studies will examine neuropathic healing. It would be 
interesting to assess chronic diabetes effects on healing, though this would necessitate use of 
insulin pellets, which will impact on the rate of healing (Goodson and Hung, 1977), and 
would preclude direct comparison to our earlier timepoints.    
Our assessment of the literature revealed a strong preference for using male animals (Table 
1), though the rationale for this remains unclear. To assess gender-specific effects on the 
STZ-DM model we conducted a second experiment comparing 6 weeks post-STZ-DM (n=9) 
versus non-diabetic (n=8) groups of female rats. Our macroscopic assessment reveals a 
significant delay after 6 weeks of diabetes, although the magnitude of difference was smaller 
than in males (Figure S1A). We could find no delay to repair by any histological measure in 
female rats (Figure S1B-D). Re-epithelialisation data were surprising given the pronounced 
delay observed in males (Compare Figure S1d to Figure 1f). Our data indicate that DM 
impaired healing is less pronounced in female rats. The underlying cause of this gender 
dichotomy remains unclear, though it may be related to the effects of sex steroid hormones 
(Ashcroft et al., 1997, Gilliver et al., 2009).  
Collectively, these data indicate that numerous published studies have been performed using 
diabetic animals that display hyperglycaemia, but have not yet established a delayed healing 
phenotype, rendering the published observations invalid. While some may argue that in 
longer term post-wound studies rats will develop an impaired healing phenotype over the 
experimental window, early work showed that the initial wound response is critical for 
overall healing outcome (Seifter et al., 1981). Our study employed a small wound to correlate 
healing efficiency with a point in time, though this will not be the optimal approach for all 
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research questions. Our data highlight the importance of clear experimental design based on 
carefully validated wound models, in order to ensure that any treatment (e.g. drug) effect can 
be demonstrated, while reducing the overall requirements for animal use. Finally, our 
literature searches over the course of this study highlight an urgent need to improve the detail 
in reported experimental methodology, to include the age/weight, sex, strain and in the case 
of the STZ model the time post-STZ-DM induction, to allow the work to be properly 
compared to existing literature. 
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Figure Legends 
Figure 1. Profiling development of impaired wound healing following STZ induced 
diabetes. Wounds in male animals following 3 or 6 weeks of diabetes, were compared to a 
non-diabetic (ND) control. Representative macroscopic images of wounds at day 5 (a), were 
used to assess the wound surface area (b). Histology was taken through the centre of the 
wounds (c), to quantify the percentage of re-epithelialisation (d), wound width (e) and area of 
granulation tissue (f). Immunohistochemistry was used to assess for inflammation (Cd68; g), 
collagen deposition (Massons trichrome; h) and angiogenesis (Vwf; i). Bars expressed as 
mean +/- SEM, n=4 animals (6 week group) and 6 animals (ND and 3 week groups). * 
P<0.05, ** P<0.01, *** P<0.001. Scale bar =5mm (a) and 1mm (c).  
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Table 1. Publications in 2016 utilising a Streptozotocin induced diabetes, rat wound healing model*
Group size Strain sex weight/age wound model STZ induction  Impaired healing vs non-diabetic? Reference  
1 n=6 Wistar Not stated 250-300g 1cm x 1cm circular excision Not stated Yes Int J Biol Macromol. 2016 Aug 2;92:1162-1168 
2 n=5-6 Sprague Dawley Male 7wk 2cm diameter circular excision up to 4 weeks Yes PLoS One. 2016 Jul 12;11(7):e0158647. 
3 Not stated Sprague Dawley Not stated 250-300g 1.5cm x 1.5cm square excision Not stated No non-diabetic control arm  AAPS PharmSciTech. Epub 2016 Jun 29.  
4 n=8 Wistar Not stated ~200g (5wk) 12mm diameter circular excision 10 days Not assessed Life Sci. 2016 May 1;152:67-75. 
5 n=3 Sprague Dawley Male 300-325g 6mm diameter circular excision 3 weeks Yes J Diabetes Res. 2016;2016:5782904. 
6 n=6 Wistar Male 150-250g 6mm diameter circular excision Not stated Yes Drug Des Devel Ther. 2016 May 24;10:1715-30
7 n=8 Sprague Dawley Male Not stated 1cm diameter circular excision 3 Days No non-diabetic control arm  J Ethnopharmacol. 2016 Aug 2;189:277-89.
8 n=8 Wistar Male 300-340g 6mm diameter circular excision 21 days No non-diabetic control arm  Mol Cell Biochem. 2016 Jun;417(1-2):119-33.
9 n=6 Wistar Not stated 150-200g 6mm diameter circular excision Not stated No non-diabetic control arm  Pharm Biol. 2016 May 14:1-5. 
10 n=12 Wistar Not stated 4 month 6cm x 5cm rectangular excision 4 weeks Yes Cell Transplant. 2016;25(1):71-81.  
11 n=6 Lewis Not stated 180-220g (6-9wks) 1.5cm diameter circular excision, splinted 4 weeks No non-diabetic control arm  J Diabetes Complications. 2016 Sep 14. pii: S1056
12 n=4-9 Wistar Male Not stated Circular wound area 10mm2 15 days Yes PLoS One. 2016 Oct 20;11(10):e0165115. 
13 n=6 Sprague Dawley Not Stated 6 wk 8mm diameter circular excision Not stated Not assessed Adv Healthc Mater. Epub 2016 Nov 2. 
14 n=20 Sprague Dawley Male 300-400g 2cm x 2cm square wound 7 days No non-diabetic control arm  Arch Dermatol Res. 2016 Jan;308(1):21-9. 
15 n=5 Wistar Male 180-22g 2cm x 2cm square wound 14 days No non-diabetic control arm  Int Immunopharmacol. 2016 Jan;30:137-49. 
16 n=8 Sprague Dawley Male 300-400 2cm x 2cm square wound 16 days Not assessed Peptides. 2016 Apr;78:1-10. 
17 n=5 Not stated Male 250 +/- 50g 2cm diameter circular excision Not stated Yes Sci Rep. 2016 Feb 23;6:19144. 
18 n=10 Sprague Dawley Male 250-300g 15mm diameter circular excision 14 days No non-diabetic control arm  Int J Biol Sci. 2016 Nov 25;12(12):1472-1487. 
19 n=6 Sprague Dawley Mixed 250-350g Circular wound area ~500mm2 4 days No non-diabetic control arm  J Intercult Ethnopharmacol. 2016 Sep 25;5(4):434
20 n=12 Wistar Male 200 +/-20g 6mm diameter circular excision 1 month Yes J Sci Food Agric. 2016 May;96(7):2337-43.  
21 n=24 Not stated Not stated 300-310g 6mm diameter circular excision Not stated No non-diabetic control arm  Iran J Pharm Res. 2016 Spring;15(2):583-9. 
22 n=15 Wistar Male 200-220g 2cm diameter circular excision 7 days Not assessed BMC Complement Altern Med. 2016 Oct 6;16(1):386.
23 n=8 Sprague Dawley Male 210-240g 6mm diameter circular excision 3 days Not assessed J Ayurveda Integr Med. 2016 Oct - Dec;7(4):198-
24 n=8 Wistar Female Not stated 6mm diameter circular excision Not stated No non-diabetic control arm  Arch Med Sci. 2016 Dec 1;12(6):1370-1376. 
25 n=6-8 Sprague Dawley Male 200-300g (6-8wks) 2cm diameter circular excision Not stated Yes J Surg Res. 2017 Feb;208:93-103.  
26 n=6 Sprague Dawley Female 150-200g (4-6wks) 5mm circular diameter excision to hindfoot 4 weeks No non-diabetic control arm  Stem Cell Res Ther. 2016 Oct 22;7(1):155. 
27 n=12 Sprague Dawley Mixed 200-250g (3 months) 1.8cm diameter wound 3 weeks No non-diabetic control arm  Neural Regen Res. 2016 Mar;11(3):493-501.  
28 n=7-10 Sprague Dawley Male 290+/-10g 10mm diameter circular excision 4 weeks Yes J Diabetes Res. 2016;2016:5639129.  
*42 pubmed listed publications were identified from 2016 using the search terms “streptozotocin skin wound healing rat”. Only studies incorporating an in vivo excisional injury model were included for comparison. Papers that were not reported in English were al
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